AngloGold Ashanti Limited (NYSE: AU) shares are 16.61% up in the year-to-date (YTD) period and have moved 1.92% or $0.49 higher in the latest trading session. Comparatively, the stock is up 30.32% over the trailing 3-month period. If we look at the shorter duration, its week performance is 3.58% and 45.21% over the month.
On June 27, 2019, BMO Capital Markets recommended the AU stock is a Outperform, while earlier, BofA/Merrill had Upgrade the stock as a Neutral on April 21, 2020. 9 analysts offering the recommendations for the stock have a consensus rating of 2.50 to suggest that the AU stock is a “Moderate Sell. 1 of the 9 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 4 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $26.05 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $24.88. The forecasts give the AngloGold Ashanti Limited stock a price target range of $38.54 on the higher side while at least one analyst think the stock could plunge to a low of $13.13. The two limits represent an upside potential of 32.41% or -98.4%.
For the current year, earnings should grow to an average of $1.08, down -10.60% from $0.51 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between $0.88 and $0.91. Wall Street estimates earnings per share to be at an average of $1.9 for the next year.
CRISPR Therapeutics AG (NASDAQ:CRSP), on the other hand, is trading around $52.00 with a market cap of $3.16B and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $74.25 and spell out a more modest performance – a 29.97% return. Some analysts are even forecasting -$4.51 per share in earnings this year on a short term (1 year) basis.
Insiders have transacted a total of 15 times at CRISPR Therapeutics AG over the last 6 months, with insider purchases undertaken 6 times and accounting for 67,451 shares. Insider sales totaled 93,961 shares over the same period, with these deals completed in 9 transactions. Looking at these numbers, we realize that net purchases over that period are -3.0 shares. Insiders now hold a total of 12.78M shares after the latest sales, with 0.60% net shares purchased.
Insiders own 0.40% of the company shares, while shares held by institutions stand at 54.30% with a share float percentage of 48.07M. Investors are also buoyed by the number of investors in a company, with CRISPR Therapeutics AG having a total of 339 institutions that hold shares in the company. The top two institutional holders are Versant Venture Management, LLC with over 4.21 million shares worth more than $178.36 million. As of Mar 30, 2020, Versant Venture Management, LLC held 6.91% of shares outstanding.
The other major institutional holder is Nikko Asset Management Americas, Inc., with the investment firm holding over 3.05 million shares as of Dec 30, 2019. The firm’s total holdings are worth over $185.73 million and represent 5.01% of shares outstanding.